Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders

Blood

Volumn 117, Issue 16, 2011, Pages 4315-4322

  Ouyang, Jing ^a   Juszczynski, Przemyslaw ^a   Rodig, Scott J ^b   Green, Michael R ^a   O'Donnell, Evan ^a   Currie, Treeve ^b   Armant, Myriam ^c   Takeyama, Kunihiko ^a   Monti, Stefano ^d   Rabinovich, Gabriel A ^e   Ritz, Jerome ^a   Kutok, Jeffery L ^b   Shipp, Margaret A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; GALECTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LATENT MEMBRANE PROTEIN 1; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DEPLETION; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOBLASTOID CELL; LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TH1 CELL; TH17 CELL; TUMOR BIOPSY; VIRUS INHIBITION;

EID: 79955954714     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-320481     Document Type: Article

References (41)

1. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9(5):338-352.
2. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29-41. (Pubitemid 40052323)
3. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5(3):241-251. (Pubitemid 38402116)
4. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007;104(32):13134-13139. (Pubitemid 351737605)
5. Toscano MA, Bianco GA, Ilarregui JM, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 2007;8(8):825-834. (Pubitemid 47099035)
6. Ilarregui JM, Croci DO, Bianco GA. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 2009;10(9):981-991.
7. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappaB. EMBO J. 2002;21(15):4104-4113. (Pubitemid 34857442)
8. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114(19):4002-4008.
9. Snow AL, Martinez OM. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant. 2007;7(2):271-277. (Pubitemid 46096319)
10. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 2008;49(suppl 1):27-34.
11. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75-82. (Pubitemid 33741978)
12. Young L, Rickinson A. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-768. (Pubitemid 39331148)
13. Vockerodt M, Morgan S, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1 reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol. 2008;216(1):83-92.
14. Portis T, Dyck P, Longnecker R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;102(12):4166-4178. (Pubitemid 37487004)
15. Nalesnik MA, Zeevi A, Randhawa PS, et al. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant. 1999;13(1, pt 1):39-44. (Pubitemid 29110387)
16. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
17. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer. 2005;92(7):1188-1192. (Pubitemid 40604390)
18. St-Pierre C, Ouellet M, Tremblay MJ, Sato S. Galectin-1 and HIV-1 infection. Methods Enzymol. 2010;480(7):267-294.
19. Vasta GR. Roles of galectins in infection. Nat Rev Microbiol. 2009;7(6):424-438.
20. Küppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003;111(4):529-537. (Pubitemid 36228010)
21. Storey J, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100(16):9440-9445. (Pubitemid 37033947)
22. Rodig SJ, Ouyang J, Juszczynski P, et al. AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008;14(11):3338-3344.
23. Feuerhake F, Kutok J, Monti S, et al. NFkappaB activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106(4):1392-1399. (Pubitemid 41129606)
24. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 2006;26(14):5348-5359. (Pubitemid 44036204)
25. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105(5):1898-1904. (Pubitemid 40731770)
26. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;28(1-2): 65-78. (Pubitemid 37324571)
27. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997;16(21):6478-6485. (Pubitemid 27483273)
28. Chen SY, Lu J, Shih YC, Tsai CH. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol. 2002;76(18):9556-9561.
29. Song X, Tao YG, Deng XY, et al. Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein-Barr virus encoded latent membrane protein 1. Cell Signal. 2004;16(10):1153-1162. (Pubitemid 38900518)
30. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A. 1998;95(20):11963-11968. (Pubitemid 28460522)
31. Merchant M, Swart R, Katzman RB, et al. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function. Int Rev Immunol. 2001;20(6):805-835. (Pubitemid 34096207)
32. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi M. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22(5):261-281.
33. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006;66(8):3963-3966.
34. Lee S, Park J, Park E, Chung C, Kang S, Bang O. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol. 2005;205(2):270-277. (Pubitemid 41428910)
35. Macián F, Lopez-Rodroguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20(19):2476-2489. (Pubitemid 32531304)
36. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin's lymphoma. Blood. 2007;110(4):1326-1329. (Pubitemid 47281432)
37. Juszczynski P, Rodig SJ, Ouyang J, et al. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein, Galectin-1. Clin Cancer Res. 2010;16(7):2122-2130.
38. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089-1096. (Pubitemid 40216472)
39. Leach D, Krummel M, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736. (Pubitemid 26102823)
40. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37(5):473-84.
41. Salatino M, Rabinovich GA. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview. Methods Mol Biol. 2011;677:355-374.